Ellis, R. W. & Brown, K. R. Combination Vaccines (Academic Press, 1997).
Hausdorff, W. P. et al. Facilitating the development of urgently required combination vaccines. Lancet Glob. Health S2214-109X, 00092–00095 (2024).
Skibinski, D. A. G., Baudner, B. C., Singh, M. & O’Hagan, D. T. Combination vaccines. J. Glob. Infect. Dis. 3, 63–72 (2011).
Maman, K. et al. The value of childhood combination vaccines: from beliefs to evidence. Hum. Vaccines Immunother. 11, 2132–2141 (2015).
Kalies, H. et al. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr. Infect. Dis. J. 25, 507–512 (2006).
Kowalzik, F., Faber, J. & Knuf, M. MMR and MMRV vaccines. Vaccine 36, 5402–5407 (2018).
Dodd, D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am. J. Manag. Care 9, S6–S12 (2003).
Esposito, S. & Principi, N. Impacts of the 13-valent pneumococcal conjugate vaccine in children. J. Immunol. Res. 2015, 591580 (2015).
Mariani, L., Preti, M., Cristoforoni, P., Stigliano, C. M. & Perino, A. Overview of the benefits and potential issues of the nonavalent HPV vaccine. Int. J. Gynecol. Obstet. 136, 258–265 (2017).
Cohen, A. A. et al. Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models. Science 377, eabq0839 (2022).
Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 371, 735–741 (2021).
Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553–559 (2021).
Ma, X. et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53, 1315–1330.e1319 (2020).
Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623–628 (2021).
Swanson, K. A. et al. A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. Sci. Immunol. 5, eaba6466 (2020).
Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367–1382.e1317 (2020).
Brouwer, P. J. M. et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184, 1188–1200.e1119 (2021).
Kelly, H. G. et al. Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. JCI Insight 5, e136653 (2020).
Wang, W. et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat. Nanotechnol. 15, 406–416 (2020).
Jacob-Dolan, C. et al. Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques. npj Vaccines 8, 23 (2023).
Zhu, F.-C. et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376, 895–902 (2010).
Chen, J. et al. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci. Bull. 67, 1372–1387 (2022).
Koenig, P.-A. et al. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science 371, eabe6230 (2021).
Li, S. W. et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 23, 2893–2901 (2005).
Huang, S. et al. Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 403, 813–823 (2024).
Li, S.-W. et al. Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J. Biol. Chem. 280, 3400–3406 (2005).
Zhang, J. et al. Long-term efficacy of a hepatitis E vaccine. N. Engl. J. Med. 372, 914–922 (2015).
Li, S.-W. et al. The development of a recombinant hepatitis E vaccine HEV 239. Hum. Vaccines Immunother. 11, 908–914 (2015).
Huang, X., Wang, X., Zhang, J., Xia, N. & Zhao, Q. Escherichia coli-derived virus-like particles in vaccine development. npj Vaccines 2, 3 (2017).
Fridy, P. C., Rout, M. P. & Ketaren, N. E. Nanobodies: from high-throughput identification to therapeutic development. Mol. Cell. Proteom. 23, 100865 (2024).
Zare, H. et al. Nanobodies, the potent agents to detect and treat the coronavirus infections: a systematic review. Mol. Cell. Probes 55, 101692 (2021).
Yang, C. et al. Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts. Protein Sci. 22, 314–326 (2013).
Zhang, X. et al. A shared N-terminal hydrophobic tail for the formation of nanoparticulates. Nanomedicine 11, 2289–2303 (2016).
Sun, X., Zhou, C., Xia, S. & Chen, X. Small molecule-nanobody conjugate induced proximity controls intracellular processes and modulates endogenous unligandable targets. Nat. Commun. 14, 1635 (2023).
Tang, X. et al. Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc. Natl Acad. Sci. USA 108, 10266–10271 (2011).
Zhao, Q., Li, S., Yu, H., Xia, N. & Modis, Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol. 31, 654–663 (2013).
Gu, Y. et al. Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Res. 25, 604–620 (2015).
Krarup, A. et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat. Commun. 6, 8143 (2015).
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
Li, T. et al. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nat. Commun. 12, 5652 (2021).
McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592–598 (2013).
De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137–148 (2015).
Young, C. & Brink, R. The unique biology of germinal center B cells. Immunity 54, 1652–1664 (2021).
Mesin, L., Ersching, J. & Victora, G. D. Germinal center B cell dynamics. Immunity 45, 471–482 (2016).
Wu, Y. et al. Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine. Cell Host Microbe 30, 1732–1744.e1737 (2022).
Wu, Y. et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci. Transl. Med. 13, eabg1143 (2021).
Zhang, X. et al. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin®. Vaccine 32, 4039–4050 (2014).
Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).
Didierlaurent, A. M. et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J. Immunol. 193, 1920–1930 (2014).
Pichyangkul, S. et al. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates. Infect. Immun. 76, 229–238 (2008).
Vekemans, J., Leach, A. & Cohen, J. Development of the RTS,S/AS malaria candidate vaccine. Vaccine 27, G67–G71 (2009).
van Erp, E. A. et al. Pathogenesis of respiratory syncytial virus infection in BALB/c mice differs between intratracheal and intranasal inoculation. Viruses 11, 508 (2019).
Bournazos, S., Gupta, A. & Ravetch, J. V. The role of IgG Fc receptors in antibody-dependent enhancement. Nat. Rev. Immunol. 20, 633–643 (2020).
Munoz, F. M. et al. Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 39, 3053–3066 (2021).
Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46–61 (2018).
Lin, M. et al. A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus. Nat. Commun. 16, 1386 (2025).
Zhang, Y. et al. Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. Cell Rep. 38, 110558 (2022).
Chang, L. et al. The prevalence of antibodies to SARS-CoV-2 among blood donors in China. Nat. Commun. 12, 1383 (2021).
Li, T. et al. Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses. Nat. Commun. 13, 5182 (2022).
Liu, C. et al. An optimized high-throughput neutralization assay for hepatitis E virus (HEV) involving detection of secreted Porf2. Viruses 11, 64 (2019).
